A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Trial Profile

A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Apatinib (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 16 Feb 2016 Results published in the Journal of Clinical Oncology
    • 03 Jun 2014 Primary endpoint 'Overall-survival-duration' has been met.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top